# Gilead Sciences (GILD) financials

Gilead Sciences reported revenue of $29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.4% from fiscal 2024. Net income was $8.51 billion and diluted earnings per share $6.78.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $8.30 billion, up 6.8% from a year earlier.

Source: Gilead Sciences's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/GILD. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Gilead Sciences reported revenue of $8.30 billion, up 6.8% from a year earlier, net income of $2.43 billion and diluted earnings per share of $1.94 against $2.43 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 29 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $8.30B | $7.77B | +6.8% |
| Gross profit | $6.73B | $6.20B | +8.5% |
| Gross margin | 81.1% | 79.8% | +1.3 pts |
| Operating income | $3.46B | $3.33B | +4.1% |
| Operating margin | 41.7% | 42.8% | −1.1 pts |
| Net income | $2.43B | $3.05B | −20.4% |
| Diluted EPS | $1.94 | $2.43 | −20.2% |
| Operating cash flow | $5.04B | $4.11B | +22.6% |
| Capital expenditure | $237.0M | $147.0M | +61.2% |
| Free cash flow | $4.80B | $3.96B | +21.1% |

Page: https://aapwire.com/stocks/GILD/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Revenue growth | −6.9% | −14.1% | −15.2% | +1.5% | +10.0% | +10.6% | −0.1% | −0.6% | +6.0% | +2.4% |
| Gross profit | $26.13B | $21.74B | $17.27B | $17.77B | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| Operating income | $17.63B | $14.12B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B |
| Net income | $13.50B | $4.63B | $5.46B | $5.39B | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B |
| Diluted EPS | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Operating cash flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| Capital expenditure | $748.0M | $590.0M | $924.0M | $825.0M | $650.0M | $579.0M | $728.0M | $585.0M | $523.0M | $563.0M |
| Free cash flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B |
| Gross margin | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Operating margin | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Cash and equivalents | $8.23B | $7.59B | $17.94B | $11.63B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B |
| Total debt | $26.35B | $33.54B | $27.32B | $25.32B | $32.12B | $27.29B | $25.81B | $25.66B | $27.32B | $25.54B |
| Shareholders' equity | $18.89B | $20.44B | $21.39B | $22.52B | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B |
| Diluted shares | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Dividends per share | $1.84 | $2.08 | $2.28 | $2.52 | $2.72 | $2.84 | $2.92 | $3.00 | $3.08 | $3.16 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.80B | $8.30B |
| Revenue, year on year | +6.4% | −0.3% | +1.8% | +3.0% | +4.7% | +4.4% | +10.2% | +6.8% |
| Gross margin | 79.1% | 76.9% | 78.8% | 79.8% | 79.5% | 79.2% | 79.8% | 81.1% |
| Operating income | $2.45B | $2.24B | $2.47B | $3.33B | $1.98B | $2.59B | −$10.39B | $3.46B |
| Net income | $1.78B | $1.31B | $1.96B | $3.05B | $2.18B | $2.02B | −$10.50B | $2.43B |
| Diluted EPS | $1.39 | $1.04 | $1.56 | $2.43 | $1.74 | $1.61 | −$8.45 | $1.94 |
| Free cash flow | $2.83B | $1.65B | $720.0M | $3.96B | $3.12B | $2.43B | $3.43B | $4.80B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Product sales](https://aapwire.com/stocks/GILD/kpi/product-sales) | $8.3B | quarter to 30 Sep 2026 | up 12.9% |
| [Biktarvy revenue](https://aapwire.com/stocks/GILD/kpi/biktarvy-revenue) | $4.1B | quarter to 30 Sep 2026 | up 10.1% |
| [Descovy revenue](https://aapwire.com/stocks/GILD/kpi/descovy-revenue) | $1.0B | quarter to 30 Sep 2026 | up 49.2% |
| [Trodelvy revenue](https://aapwire.com/stocks/GILD/kpi/trodelvy-revenue) | $506.0M | quarter to 30 Sep 2026 | up 41.7% |
| [Genvoya revenue](https://aapwire.com/stocks/GILD/kpi/genvoya-revenue) | $339.0M | quarter to 30 Sep 2026 | down 10.1% |
| [Vemlidy revenue](https://aapwire.com/stocks/GILD/kpi/vemlidy-revenue) | $333.0M | quarter to 30 Sep 2026 | up 18.9% |
| [Yeztugo revenue](https://aapwire.com/stocks/GILD/kpi/yeztugo-revenue) | $305.0M | quarter to 30 Sep 2026 | up 682.1% |
| [Yescarta revenue](https://aapwire.com/stocks/GILD/kpi/yescarta-revenue) | $294.0M | quarter to 30 Sep 2026 | down 15.8% |
| [Odefsey revenue](https://aapwire.com/stocks/GILD/kpi/odefsey-revenue) | $286.0M | quarter to 30 Sep 2026 | up 3.2% |
| [Sofosbuvir/Velpatasvir revenue](https://aapwire.com/stocks/GILD/kpi/sofosbuvir-velpatasvir-revenue) | $274.0M | quarter to 30 Sep 2026 | down 11.3% |
| [Livdelzi revenue](https://aapwire.com/stocks/GILD/kpi/livdelzi-revenue) | $203.0M | quarter to 30 Sep 2026 | up 93.3% |
| [Symtuza - Revenue share revenue](https://aapwire.com/stocks/GILD/kpi/symtuza-revenue-share-revenue) | $132.0M | quarter to 30 Sep 2026 | up 6.5% |
| [AmBisome revenue](https://aapwire.com/stocks/GILD/kpi/ambisome-revenue) | $99.0M | quarter to 30 Sep 2026 | down 19.5% |
| [Veklury revenue](https://aapwire.com/stocks/GILD/kpi/veklury-revenue) | $86.0M | quarter to 30 Sep 2026 | down 69.0% |
| [Tecartus revenue](https://aapwire.com/stocks/GILD/kpi/tecartus-revenue) | $60.0M | quarter to 30 Sep 2026 | down 27.7% |
| [Royalty, contract and other revenues](https://aapwire.com/stocks/GILD/kpi/royalty-contract-and-other-revenues) | $11.0M | quarter to 30 Sep 2026 | down 97.4% |
| [United States revenue](https://aapwire.com/stocks/GILD/kpi/united-states-revenue) | $6.4B | quarter to 30 Sep 2026 | up 20.5% |
| [Europe revenue](https://aapwire.com/stocks/GILD/kpi/europe-revenue) | $1.1B | quarter to 30 Sep 2026 | down 31.5% |
| [Rest of World revenue](https://aapwire.com/stocks/GILD/kpi/rest-of-world-revenue) | $872.0M | quarter to 30 Sep 2026 | down 6.5% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
